Top Strong Buy Stocks for October 31: PMT, NWG, and Others
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2025
0mins
Source: NASDAQ.COM
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including PennyMac Mortgage Investment Trust, NatWest Group, Phibro Animal Health, Centene, and ACNB, all of which have seen positive earnings estimate revisions over the past 60 days.
Earnings Growth: Each of the highlighted companies has experienced an increase in the Zacks Consensus Estimate for their current year earnings, with PennyMac leading at 10.3% growth.
Investment Opportunities: The article suggests that these stocks are under the radar of Wall Street, presenting a unique opportunity for investors to potentially capitalize on significant growth, with previous recommendations yielding returns of +171%, +209%, and +232%.
Expert Recommendations: Zacks Investment Research offers a free report on the "7 Best Stocks for the Next 30 Days," encouraging investors to consider these handpicked stocks for potential high returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAHC
Wall Street analysts forecast PAHC stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 31.870
Low
45.00
Averages
47.50
High
50.00
Current: 31.870
Low
45.00
Averages
47.50
High
50.00
About PAHC
Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phibro Animal Health Director Acquires Shares Amid Market Challenges
- Share Acquisition Details: E. Thomas Corcoran, Director of Phibro Animal Health, acquired 10,000 shares at a weighted average price of $31.77 on May 29, 2026, totaling approximately $318,000, indicating his bullish outlook on the company's future despite market challenges.
- Ownership Increase: Following this transaction, Corcoran's direct holdings rose to 41,459 shares, a 31.79% increase, which enhances his capacity for future acquisitions, although the market's reaction to the company remains tepid.
- Market Reaction Analysis: While Corcoran's purchase suggests optimism about the company's prospects, Phibro's stock has dropped about 47% since April, primarily due to Brazil's ban on certain antibiotic feed additives, reflecting market concerns about the company's future performance.
- Financial Performance Overview: In the fiscal third quarter of 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million, and despite anticipated declines in antibiotic feed additive sales in Brazil, the company expects net sales to range between $1.46 billion and $1.5 billion for fiscal 2026, demonstrating resilience in the market.
See More
Corcoran Increases Phibro Stock Holdings by 31.79%
- Share Acquisition Details: E. Thomas Corcoran purchased 10,000 shares of Phibro Animal Health on May 29, 2026, at a weighted average price of $31.77 per share, totaling approximately $318,000, which increased his direct ownership by 31.79%, bringing his total holdings to 41,459 shares.
- Market Reaction Analysis: Despite Corcoran's purchase indicating a bullish outlook for the company, Phibro's stock has dropped about 47% since April, primarily due to Brazil's prohibition on certain antibiotic feed additives, which has negatively impacted market sentiment.
- Financial Performance Overview: For the fiscal third quarter ending March 31, 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million; however, the company anticipates a downturn in antibiotic feed additive sales in Brazil, projecting net sales for fiscal 2026 to be between $1.46 billion and $1.5 billion.
- Industry Outlook: Phibro is launching a digital platform in the Brazilian market to facilitate the veterinary prescription process, and despite regulatory challenges, the company maintains a competitive position in the animal health industry through its diversified product portfolio and established distribution channels, indicating long-term growth potential.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Phibro (PAHC) Q3 2026 Earnings Transcript
See More
Phibro Animal Health CEO Sells Shares Amid Transition
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, indirectly sold 18,608 shares of common stock between May 5 and May 7, 2026, totaling approximately $1 million, which reduced his indirect holdings from 74,760 to 56,152 shares, indicating a potential decrease in confidence regarding the company's future.
- Trading Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 11, 2025, reflecting Bendheim's strategic adjustment ahead of his transition from CEO to Executive Chairman, suggesting a cautious approach during the governance change.
- Ownership Analysis: Despite the sale, Bendheim retains 16,840 direct shares and 56,152 indirect shares, totaling 449,485 Class A common stock shares convertible into common stock, indicating he still maintains significant economic interest and influence within the company.
- Company Performance Overview: Phibro Animal Health reported a revenue of $1.5 billion and a net income of $95.23 million, with a dividend yield of 1.88% and a 50.21% increase in stock price over the past year, highlighting the company's strong performance and growth potential in the animal health product market.
See More
Phibro Animal Health CEO Sells Shares
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, sold 18,608 shares of common stock between May 5 and May 7, 2026, representing about 20% of his total reported ownership, indicating a gradual reduction in his stake in the company.
- Transaction Value Analysis: The sale, calculated at a weighted average purchase price of $54.61 per share according to SEC Form 4, reflects a significant transaction value, although Bendheim retains a solid ownership stake, suggesting confidence in the company's future.
- Management Transition Context: Bendheim established the sale plan in December 2025, coinciding with his announcement to step down as CEO on July 1, 2026, transitioning to Executive Chairman, which provides a reasonable context for his gradual divestment, typical for founder-era executives.
- Future Outlook and Challenges: With Daniel Bendheim taking over, investor focus will shift to sustaining the integration of Phibro's recent acquisition of Zoetis' feed additive portfolio and maintaining margin expansion, which will directly impact the company's long-term growth potential.
See More
Phibro Animal Health Director Acquires Shares Amid Market Challenges
- Share Acquisition Details: E. Thomas Corcoran, Director of Phibro Animal Health, acquired 10,000 shares at a weighted average price of $31.77 on May 29, 2026, totaling approximately $318,000, indicating his bullish outlook on the company's future despite market challenges.
- Ownership Increase: Following this transaction, Corcoran's direct holdings rose to 41,459 shares, a 31.79% increase, which enhances his capacity for future acquisitions, although the market's reaction to the company remains tepid.
- Market Reaction Analysis: While Corcoran's purchase suggests optimism about the company's prospects, Phibro's stock has dropped about 47% since April, primarily due to Brazil's ban on certain antibiotic feed additives, reflecting market concerns about the company's future performance.
- Financial Performance Overview: In the fiscal third quarter of 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million, and despite anticipated declines in antibiotic feed additive sales in Brazil, the company expects net sales to range between $1.46 billion and $1.5 billion for fiscal 2026, demonstrating resilience in the market.
See More
Corcoran Increases Phibro Stock Holdings by 31.79%
- Share Acquisition Details: E. Thomas Corcoran purchased 10,000 shares of Phibro Animal Health on May 29, 2026, at a weighted average price of $31.77 per share, totaling approximately $318,000, which increased his direct ownership by 31.79%, bringing his total holdings to 41,459 shares.
- Market Reaction Analysis: Despite Corcoran's purchase indicating a bullish outlook for the company, Phibro's stock has dropped about 47% since April, primarily due to Brazil's prohibition on certain antibiotic feed additives, which has negatively impacted market sentiment.
- Financial Performance Overview: For the fiscal third quarter ending March 31, 2026, Phibro reported a 10% year-over-year increase in net sales to $383.5 million; however, the company anticipates a downturn in antibiotic feed additive sales in Brazil, projecting net sales for fiscal 2026 to be between $1.46 billion and $1.5 billion.
- Industry Outlook: Phibro is launching a digital platform in the Brazilian market to facilitate the veterinary prescription process, and despite regulatory challenges, the company maintains a competitive position in the animal health industry through its diversified product portfolio and established distribution channels, indicating long-term growth potential.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Phibro (PAHC) Q3 2026 Earnings Transcript
See More
Phibro Animal Health CEO Sells Shares Amid Transition
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, indirectly sold 18,608 shares of common stock between May 5 and May 7, 2026, totaling approximately $1 million, which reduced his indirect holdings from 74,760 to 56,152 shares, indicating a potential decrease in confidence regarding the company's future.
- Trading Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 11, 2025, reflecting Bendheim's strategic adjustment ahead of his transition from CEO to Executive Chairman, suggesting a cautious approach during the governance change.
- Ownership Analysis: Despite the sale, Bendheim retains 16,840 direct shares and 56,152 indirect shares, totaling 449,485 Class A common stock shares convertible into common stock, indicating he still maintains significant economic interest and influence within the company.
- Company Performance Overview: Phibro Animal Health reported a revenue of $1.5 billion and a net income of $95.23 million, with a dividend yield of 1.88% and a 50.21% increase in stock price over the past year, highlighting the company's strong performance and growth potential in the animal health product market.
See More
Phibro Animal Health CEO Sells Shares
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, sold 18,608 shares of common stock between May 5 and May 7, 2026, representing about 20% of his total reported ownership, indicating a gradual reduction in his stake in the company.
- Transaction Value Analysis: The sale, calculated at a weighted average purchase price of $54.61 per share according to SEC Form 4, reflects a significant transaction value, although Bendheim retains a solid ownership stake, suggesting confidence in the company's future.
- Management Transition Context: Bendheim established the sale plan in December 2025, coinciding with his announcement to step down as CEO on July 1, 2026, transitioning to Executive Chairman, which provides a reasonable context for his gradual divestment, typical for founder-era executives.
- Future Outlook and Challenges: With Daniel Bendheim taking over, investor focus will shift to sustaining the integration of Phibro's recent acquisition of Zoetis' feed additive portfolio and maintaining margin expansion, which will directly impact the company's long-term growth potential.
See More
